New incident report
Incident Report Number: 2018-6467
Registrant Reference Number: USA-BAYERBAH-2018-US0061015 (Report 527711)
Registrant Name (Full Legal Name no abbreviations): Bayer inc
Address: 2920 Matheson Blvd
City: Mississaugua
Prov / State: ON
Country: Canada
Postal Code: L4W 5R6
Domestic Animal
Country: UNITED STATES
Prov / State: PENNSYLVANIA
PMRA Registration No. 27585 PMRA Submission No. EPA Registration No.
Product Name: advantageII small cat
Liquid
Yes
Units: mL
Site: Animal / Usage sur un animal domestique
Medical Professional
Cat / Chat
crossbred
1
Female
1.5
3.175
kg
Skin
>1 wk <=1 mo / > 1 sem < = 1 mois
<=30 min / <=30 min
System
>3 days <=1 wk / >3 jours <=1 sem
Yes
No
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 06Oct2018, the owner consulted a veterinarian and bathed the feline with a liquid dish soap as instructed. The feline was not examined. On 09Oct2018, the feline died. A necropsy examination was performed; the results were unknown. On 09Oct2018, the feline died. On 10 Oct 2018, the cat's remains were taken to another veterinary hospital. At that location, blood was removed from the remains 28 hours after death and a Chemistry panel, FeLV/FIV HW Snap test and SDMA tests were performed. Results indicated that the cat was positive for feline leukemia virus. Abnormal blood results included Glucose 338, (74-159 mg/dL), Phosphorus > 16 mg/dL, (3.1-7.6), Albumin 4.7, (2.2-4.0 g/dL), Lipase 4209, (100-1400 U/L), and SDMA 28 (0-14 ug/dL). There was no evidence of kidney disease, BUN and Creatinine were normal, and specific gravity was 1.045. A urinalysis was performed and the results were normal. Radiographs were taken, but results are unknown. A necropsy with tissue histology was performed. At the application site, there was a half inch diameter full thickness coagulative necrosis affecting the epidermis, follicular epithelium and dermal collagen. The heart had mild multifocal chronic lymphoplasmacytic and fibrosing myocarditis. The chronicity of these lesions were felt to be consistent with a potential cause of death in the patient. Other changes noted in the necropsy were thought to be due to autolytic changes associated with death.
Death
Advantage: O - Unclassifiable/unassessable Neurological sign of mydriasis and behavioural disorder of hyperactivity are unspecific and not expected with appropriate topical product use. No oral product exposure witnessed. In individual cases, dermal reaction like alopecia at the application site is possible in animals that are particular sensitive. However reported application site bleeding later of necrosis are not expected. Self-trauma or secondary bacterial infection may have aggravated the signs. Later reported death as well as later revealed severe necropsy signs of cardiovascular disorder of fibrosing myocarditis, elevated levels of glucose, phosphorus, albumin, lipase, and symmetric dimethylarginine are not expected after product application, as inconsistent with pharmaco-toxicological product profile. Product has wide margin of safety. The oral LD50 in rat is 642 mg/kg BW. 24-fold over dosage tolerated by cats without showing any side effect. Time to onset is short for initially reported signs, but long for later reported death and revealed necropsy signs. Other causes must be considered. Overall, a product relation is considered unassessable.